Noradrenergic alpha1 receptors as a novel target for the treatment of nicotine addiction. - Wikidata - wikimedia - TriplyDB

Noradrenergic alpha1 receptors as a novel target for the treatment of nicotine addiction.

Noradrenergic alpha1 receptors as a novel target for the treatment of nicotine addiction.

http://www.wikidata.org/entity/Q34661063

about

Role of cues and contexts on drug-seeking behaviour Targeting the noradrenergic system for gender-sensitive medication development for tobacco dependence Pharmacological treatment of comorbid PTSD and substance use disorder: recent progress Cocaine increases dopaminergic neuron and motor activity via midbrain α1 adrenergic signaling.Tobacco addiction and the dysregulation of brain stress systems.Effects of a selective cannabinoid CB2 agonist and antagonist on intravenous nicotine self administration and reinstatement of nicotine seeking Involvement of noradrenergic transmission in the PVN on CREB activation, TORC1 levels, and pituitary-adrenal axis activity during morphine withdrawal Nicotine self-administration research: the legacy of Steven R. Goldberg and implications for regulation, health policy, and research.Effect of prazosin and guanfacine on stress-induced reinstatement of alcohol and food seeking in rats.AM404 attenuates reinstatement of nicotine seeking induced by nicotine-associated cues and nicotine priming but does not affect nicotine- and food-taking.Restraint stress attenuates nicotine's locomotor stimulant but not discriminative stimulus effects in rats.Convergent pharmacological mechanisms in impulsivity and addiction: insights from rodent models.A translational investigation targeting stress-reactivity and prefrontal cognitive control with guanfacine for smoking cessation Stimulation of α2-adrenergic receptors in the central nucleus of the amygdala attenuates stress-induced reinstatement of nicotine seeking in rats.Dopamine D3 receptors in the basolateral amygdala and the lateral habenula modulate cue-induced reinstatement of nicotine seeking.AT-1001: a high-affinity α3β4 nAChR ligand with novel nicotine-suppressive pharmacology The selective anandamide transport inhibitor VDM11 attenuates reinstatement of nicotine seeking behaviour, but does not affect nicotine intake Effects of prazosin, an α1-adrenergic receptor antagonist, on the seeking and intake of alcohol and sucrose in alcohol-preferring (P) rats.Nicotine-taking and nicotine-seeking in C57Bl/6J mice without prior operant training or food restriction Low-dose prazosin alone and in combination with propranolol or naltrexone: effects on ethanol and sucrose seeking and self-administration in the P rat.α-1 Adrenergic receptors are localized on presynaptic elements in the nucleus accumbens and regulate mesolimbic dopamine transmission.Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans.Emerging role for corticotropin releasing factor signaling in the bed nucleus of the stria terminalis at the intersection of stress and reward.Regulation of neurological and neuropsychiatric phenotypes by locus coeruleus-derived galanin.Varenicline decreases nicotine self-administration and cue-induced reinstatement of nicotine-seeking behaviour in rats when a long pretreatment time is used.The Sensory Impact of Nicotine on Noradrenergic and Dopaminergic Neurons of the Nicotine Reward - Addiction Neurocircuitry.Effects of blockade of α4β2 and α7 nicotinic acetylcholine receptors on cue-induced reinstatement of nicotine-seeking behaviour in rats.Elevation of dopamine induced by cigarette smoking: novel insights from a [11C]-+-PHNO PET study in humans Effect of doxazosin on stress reactivity and the ability to resist smoking.Extinction bursts in rats trained to self-administer nicotine or food in 1-h daily sessions.Electrical stimulation of the insular region attenuates nicotine-taking and nicotine-seeking behaviors.Effects of disulfiram on choice behavior in a rodent gambling task: association with catecholamine levels.

P2860

Q26825476-BE701D49-6C5C-49F5-8419-A9DF79AF63B8 Q26999258-DF4832AB-7771-4D80-8B10-C1844C58535D Q27022219-E82AAE74-9463-48CF-8336-81BA964A0957 Q27311149-98EDB41E-7F07-4CC7-9153-DC3517E761C1 Q28111988-DE932F1C-F24D-4657-9C80-181DEB3A8804 Q28480387-5406EB5C-78F3-40D7-896E-9AE6C7AA3F5A Q28480798-DF0B0539-9CE6-4ADA-92A5-7429F82F6A88 Q30244252-43D59D7C-0779-4146-A91D-CD5D0DAAA02B Q30461991-4EDAA351-2D88-45F9-9631-54DF4825543D Q33759649-777052E3-045F-4D31-A332-E44F1308512C Q34115735-898C60EF-4D52-4E49-8114-257981D33145 Q34407185-70A6A348-AF1B-4887-9AF7-71D0DDC7C63F Q34454236-32F1565F-D2DB-4B12-B906-3C1CF5E7827A Q34459334-B657CF39-34AD-436A-A627-D0C7520B8AAA Q34499327-4940AC62-C0F7-4025-A71A-7F25AE973058 Q35223957-69A4485F-7627-4A49-82F2-926ABEEF32FA Q35593066-2F174846-E8DF-49CE-ABD1-D036D99CEB31 Q35670393-3B507679-29AD-4D73-92A8-51F5E12B6B1D Q35846351-AF3BB9B6-AC76-4339-ACE6-D049F442B4AA Q35858582-7B9D923A-F5F1-4C83-BB4F-A4980EFD8460 Q36100281-5550FA2B-3752-4A3F-9E65-0CE9C91C22D1 Q36252777-4547A789-56BC-4F0E-A2B0-815EB1D7E358 Q36881952-5FAB2EB9-A156-43F5-ACB0-627FE917423B Q36922331-95CE89FB-8D7E-4B0D-BE78-28547EC7AE8D Q37000172-47D44F3E-1B2E-42B0-A8F6-15C3CB18D2B5 Q37028098-D991C9F9-341A-4F82-A2CC-25C260FE9EAB Q37351302-4FB172B6-13C5-4FE1-B38A-FC3D73684619 Q37409589-1CA54151-58C3-4AEF-A585-BC0581FD60C9 Q40229079-79A56D63-BDEF-4609-A975-4C95699497F3 Q41349799-A57BB873-4749-41BD-AA6C-DF3C5AC82A89 Q43247605-9EA142DF-8B23-47CA-A024-001A8D667E36 Q47585471-BD0E9F2C-34CB-4B79-B29C-9A30CB13B43C

P2860

Noradrenergic alpha1 receptors as a novel target for the treatment of nicotine addiction.

http://www.wikidata.org/entity/Q34661063

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Noradrenergic alpha1 receptors as a novel target for the treatment of nicotine addiction.

@ast

Noradrenergic alpha1 receptors as a novel target for the treatment of nicotine addiction.

@en

Noradrenergic alpha1 receptors as a novel target for the treatment of nicotine addiction.

@nl

type

label

Noradrenergic alpha1 receptors as a novel target for the treatment of nicotine addiction.

@ast

Noradrenergic alpha1 receptors as a novel target for the treatment of nicotine addiction.

@en

Noradrenergic alpha1 receptors as a novel target for the treatment of nicotine addiction.

@nl

prefLabel

Noradrenergic alpha1 receptors as a novel target for the treatment of nicotine addiction.

@ast

Noradrenergic alpha1 receptors as a novel target for the treatment of nicotine addiction.

@en

Noradrenergic alpha1 receptors as a novel target for the treatment of nicotine addiction.

@nl

P1433

Q34661063-3601F321-CF55-461F-9986-5C3F1146CC25

P1476

Q34661063-EC9B3A25-FDC9-439B-A76D-AFF099136939

P2093

Q34661063-1A59D1FC-BE37-4117-BD31-6F10C86AECA7

Q34661063-3782C728-C16C-4B36-A4DD-9EBB24E81755

Q34661063-3BB6B7CA-4D46-455C-B1D9-006AB3439640

Q34661063-4B7451CA-0CF9-44D2-9B81-4986B0613284

Q34661063-75BBBEB7-11E6-406D-85EF-F162DB209BBA

Q34661063-CDE0F3B2-900B-4340-AAB4-8AA126E93998

P2860

Q34661063-04F238D6-F747-46B0-8D99-ED1055BBB17C

Q34661063-0E8878D0-6F49-437B-BC45-0E7A9CB29BA6

Q34661063-1912BD64-087A-4A94-8EDA-B34ADB19AF97

Q34661063-1E8C94E9-04C2-40F0-B441-6B05907FD78F

Q34661063-23B4A5BB-62E0-46AE-9E2B-5B56BF4D83F1

Q34661063-279A0005-AD6D-4659-83B1-81EFF537BCF1

Q34661063-286D85B5-57B9-4C5F-B23B-033FE316CA63

Q34661063-2FA418A2-0CAD-4912-AF60-72A9888D6FE5

Q34661063-32D1EBE8-AD45-4F14-8404-0B7A1021DCF4

Q34661063-32E47835-9F6B-4EB9-AED5-F2DF75BAA055

P2888

Q34661063-8494D007-C751-4974-B47A-9390A93BD524

P304

Q34661063-D1E5DF50-6089-4B7C-851B-01FBBF52AB89

P31

Q34661063-33AF09B1-ACCE-4ED5-91D3-89636CC989D1

P356

Q34661063-14EB90D5-E086-470D-958D-CA0FFF245D00

P407

Q34661063-EADF9A50-7C54-4CFE-9FB3-71E95A19015D

P433

Q34661063-C3CFE20D-C567-43CA-8A44-7F941CC2E119

P478

Q34661063-938EC029-4FAB-4130-90CF-931DA29E1C31

P577

Q34661063-0CFD8435-22BC-44F5-9044-C180CD94296C

P5875

Q34661063-323D741F-E075-4F3C-8FDB-627E5B19A0C1

P6179

Q34661063-6E5BFDF7-F99B-4FF5-BB8A-8D0CE8D7A6D2

P698

Q34661063-4F727D44-3E0C-4E1A-B9B6-7DF7E58DB597

P932

Q34661063-2447E5E7-F1D0-494D-BA21-CE88C32792C6

P356

P1433

Neuropsychopharmacology

P1476

Noradrenergic alpha1 receptors as a novel target for the treatment of nicotine addiction.

@en

P2093

Abhiram Pushparaj

http://www.w3.org/2001/XMLSchema#string

Benoit Forget

http://www.w3.org/2001/XMLSchema#string

Bernard Le Foll

http://www.w3.org/2001/XMLSchema#string

Carrie Wertheim

http://www.w3.org/2001/XMLSchema#string

Paola Mascia

http://www.w3.org/2001/XMLSchema#string

Steven R Goldberg

http://www.w3.org/2001/XMLSchema#string

P2860

The reinstatement model of drug relapse: history, methodology and major findings

Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats

Role of dopamine in the behavioural actions of nicotine related to addiction.

A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence.

Reboxetine: functional inhibition of monoamine transporters and nicotinic acetylcholine receptors.

There and back again: a tale of norepinephrine and drug addiction.

Principles of laboratory assessment of drug abuse liability and implications for clinical development.

Brain circuitry and the reinstatement of cocaine-seeking behavior.

Neuroplasticity within the mesoaccumbens dopamine system and its role in tobacco dependence.

Prefrontal/accumbal catecholamine system determines motivational salience attribution to both reward- and aversion-related stimuli.

P2888

P304

1751-1760

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NPP.2010.42

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42807220

http://www.w3.org/2001/XMLSchema#string

P6179

1043688164

http://www.w3.org/2001/XMLSchema#string

P698

20357760

http://www.w3.org/2001/XMLSchema#string

P932

3055474

http://www.w3.org/2001/XMLSchema#string